{"version":"1.0","provider_name":"South Africa Voice","provider_url":"https:\/\/southafricavoice.com","author_name":"South Africa Voice","author_url":"https:\/\/southafricavoice.com\/author\/southafricavoice01\/","title":"Zenas BioPharma administra a primeira dose em paciente, dando in\u00edcio \u00e0 Fase 3 do Estudo Cl\u00ednico do Obexelimab para o tratamento de doen\u00e7a relacionada \u00e0 imunoglobulina G4 (IgG4-RD) - South Africa Voice","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"yLypp2maXV\"><a href=\"https:\/\/southafricavoice.com\/zenas-biopharma-administra-a-primeira-dose-em-paciente-dando-inicio-a-fase-3-do-estudo-clinico-do-obexelimab-para-o-tratamento-de-doenca-relacionada-a-imunoglobulina-g4-igg4-rd\/\">Zenas BioPharma administra a primeira dose em paciente, dando in\u00edcio \u00e0 Fase 3 do Estudo Cl\u00ednico do Obexelimab para o tratamento de doen\u00e7a relacionada \u00e0 imunoglobulina G4 (IgG4-RD)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricavoice.com\/zenas-biopharma-administra-a-primeira-dose-em-paciente-dando-inicio-a-fase-3-do-estudo-clinico-do-obexelimab-para-o-tratamento-de-doenca-relacionada-a-imunoglobulina-g4-igg4-rd\/embed\/#?secret=yLypp2maXV\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma administra a primeira dose em paciente, dando in\u00edcio \u00e0 Fase 3 do Estudo Cl\u00ednico do Obexelimab para o tratamento de doen\u00e7a relacionada \u00e0 imunoglobulina G4 (IgG4-RD)&#8221; &#8212; South Africa Voice\" data-secret=\"yLypp2maXV\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"O estudo Global de Fase 3 INDIGO avaliar\u00e1 a efic\u00e1cia e a seguran\u00e7a do obexelimab em pacientes com IgG4-RD, uma doen\u00e7a fibroinflamat\u00f3ria cr\u00f4nica e grave que normalmente afeta m\u00faltiplos \u00f3rg\u00e3os A IgG4-RD \u00e9 a primeira de v\u00e1rias indica\u00e7\u00f5es potenciais de doen\u00e7a a serem testadas com o obexelimab, dada sua inibi\u00e7\u00e3o \u00fanica de c\u00e9lulas B n\u00e3o [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/4TLR_imX-AIuQsE9kglz1X27LoYKRwq1dMVDTpMU5OCcOZmu0DE4dB3VpwjJXl5-mjQ9ZdK84-51LTeGxyu0BoGqp2DPLTIKAtAnO2WVbDWgXKgHLV0OVUcYSunX9DwECJQ2Ca3y0tOTLa_SRK0Q5SzCOKnYjJswvP1spzRiFtSWQWbt3xP3O010RPYiDX6mPAb12A=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/NjgwZDMzMTYtNGQ1My00NTQ3LTk4MGMtYzcxMDc2NTdiYjlhLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}